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ALPHA-1 DEFICIENCY: BETTER DETECTION MAY IMPROVE OUTCOMES FOR COPD
PATIENTS
Angela Schuster PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND 58202-9037

Abstract

Literature Review

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that
results in debilitating illnesses like: emphysema, COPD, liver
disease, and panniculitis. AATD is highly under-diagnosed

A search of peer reviewed journal articles was performed
utilizing electronic databases including: PubMed, Cochrane,
and Clinical Key. Several articles published between 2002
and 2017 were retrieved and reviewed including those
regarding the pathophysiology and prevalence of alpha-1
deficiency, guidelines for testing and management of
patients with AATD, current and emergent therapies for
AATD, barriers to diagnosis, and strategies for improved
diagnosis. One systematic review of articles published
between January 2002 and December 2014 regarding
practice guidelines for diagnosis and management of AATD
patients was reviewed. An observational study published in
2010 that analyzed barriers to detection by assessing the
level of knowledge of AATD among internal medicine house
officers and respiratory therapists was included. Three
observational studies published between 2009 and 2014
aimed at analyzing processes for improving detection of
alpha-1 antitrypsin deficiency were included. Information
was also obtained from the Alpha-1 Foundation website and
personal interviews with Ronald Reilkoff, M.D. (University of
Minnesota Pulmonary, Allergy, Critical Care & Sleep
Medicine) and Mary Davis (Sales Director, Grifols USA).

based on epidemiologic and population studies that suggest
that fewer than 10% of the 60,000-100,000 individuals in
the U.S. suspected to have severely deficient alleles have
been identified ( Rahaghi et al., 2012). This study examines
strategies aimed at improving detection of AATD. The findings
indicate that utilizing flags to alert providers of the need for
AATD testing initiated by RTs or automated within EMR systems
are effective strategies for increasing testing rates and potentially
improving detection of emphysema and COPD secondary to
AATD therefore eliminating diagnostic delays and improving
prognosis for those affected.

Introduction
Alpha-1 antitrypsin deficiency (AATD) is an autosomal codominant condition resulting in decreased or absent levels of
alpha-1 antitrypsin (AAT) which is a protease produced in the
liver. This allows the uninhibited proteolytic action of
neutrophil elastase to overtake the lungs resulting in
degradation of lung tissue and early onset (prior to the fourth or
fifth decade) emphysema and chronic obstructive pulmonary
disease (COPD) (Hatipoglu, Umur & Stoller, 2016). Exposure to
environmental pollutants and cigarette smoke greatly increase
neutrophil elastase activity and therefore exacerbate lung
destruction in AATD individuals. It is thought that similar
inflammatory reactions occur in the skin resulting in vasculitis
and panniculitis. In addition, intrahepatic accumulation of the
defective protein may cause cirrhosis or primary liver
carcinoma. This condition accounts for 2%-5% of chronic
obstructive pulmonary disease cases in America (Diaz,J.A,
Minami, 2017) and is thought to be most common in
individuals of Northern European decent (Hatipoglu, Umur &
Stoller, 2016).

Discussion
Potential Barriers to Detection of AATD:
• Lack of knowledge regarding Alpha-1 among providers
and patients.
• Perception among providers that treatment is ineffective.
• Patient fear that diagnosis will affect their ability to obtain
life or health insurance or fear of emotional impact.
• Cost associated with testing.

Addressing the Barriers and Exploring Strategies to
Overcome Them:

Statement of the Problem
Despite guidelines from the American Thoracic Society and
the European Respiratory Society regarding testing for AATD,
the disorder remains highly under-diagnosed. Furthermore,
individuals report long delay times (averaging 5-7years) and
visits to multiple providers between onset of symptoms and
diagnosis which delays opportunities for lifestyle modifications
and potential treatment with augmentation therapy that may
improve prognosis(Hatipoglu, Umur & Stoller, 2016).

Research Questions
• What are the barriers to detection of AATD?
• Are there effective strategies that may be implemented
to overcome barriers to recognition and decrease
diagnostic delays allowing for interventions that may
decrease progressive loss of lung function in COPD
patients with AATD?

Knowledge of AATD
Taliercio, Chatburn, and Stoller, 2010, conducted a study
assessing the knowledge of AATD among internal
medicine house officers and respiratory therapists (RTs) at
the Cleveland Clinic. There was no statistically significant
difference between the physician and RTs mean scores of
54% and 52%, P= .25. Half of physician scores were
below 55% with that being the median for the group.
The median for RTs was 50%. Those who rated
themselves as “somewhat knowledgeable” on selfassessment scored highest with physician scores of
60% correct and RT scores of 56%, P= < .001. Physician
scores did not change based on post-graduate education
level (P= .94), but RTs with 4-year degrees had a higher
mean score than those graduating from 2 year programs
(56% vs 50%) (Taliercio, Chatburn, & Stoller, 2010).

 Effectiveness of Augmentation with Human Plasma
Derived Alpha-1 Protein
The American Thoracic Society currently recommends
augmentation therapy with Alpha-1 antitrypsin derived from
human plasma for mild to moderate COPD (FEV1 of 35%65%) and alpha-1 antitrypsin deficiency. Despite early
randomized control trials that failed to prove improvement in
lung function of AATD individuals receiving augmentation
therapy while using spirometry and FEV1 as measures,
more recent studies have noted reductions in the loss of
lung density when subjects were assessed with Computed
Tomography rather than spirometry. In addition,
observational benefits such as: decreased mortality,
reduction of inflammatory markers in sputum, and reduced
rates of respiratory tract infections have been noted in those
who received augmentation compared to those who did not.
The FDA has approved augmentation therapy for mild to
moderate COPD due to AATD on the basis of biochemical
efficacy, which is described as the ability to raise serum
levels to the established protective threshold of 11µM or
57mg/dL (Hatipoglu, Umur & Stoller, 2016).
 Utilizing Respiratory Therapists and Automated EMR
algorithms to flag patients for testing:
Rahaghi et al. (2009) analyzed the effects of a physician
alert for AATD testing generated by respiratory therapists
following abnormal PFT results. During the pre-alert
period, 6% of included patients underwent testing for
AATD compared to 13% in the physician alert phase
(p=0.04). In 2011,Jain, McCarthy, Xu, and Stoller conducted
a similar study at the Cleveland Clinic in Ohio utilizing an
EMR based flag for testing. The study included 979 subjects
during a pre-alert period. 4.7% were referred for testing
resulting in 8.9% found to have AATD based on serum
levels. Phenotyping of those with low serum levels, resulted
in 3.2% with genotype PI ZZ. During the alert period, 624
patients were determined eligible and the rate of testing
increased substantially to 15.1%, P < 0.001. In conclusion,
the studies strongly suggested that utilizing respiratory
therapists and EMR flags to identify individuals for testing
based on PFT results substantially increased rates for
testing individuals clinically indicated at risk for AATD
(Rahaghi et al., 2009).
 The Genetic Information Nondiscrimination Act (GINA)
of 2008 protects those diagnosed with genetic
disorders from discrimination when applying for
health insurance and employment (NIH, 2013)
 Overcoming the Cost of Testing and Providing Patient
and Provider resources regarding diagnosis and
Management of AATD:
The Alpha-1 Foundation and many of the pharmaceutical
manufacturers of augmentation offer free testing kits for
evaluation of AAT serum level and genotype using dried blood
spot PCR eliminating this barrier. In addition, the Alpha-1
Foundation offers genetic counseling services for those
identified with AATD. In addition, the foundation provides and
array of educational offerings regarding AATD diagnosis and
treatment to clinicians.(Alpha-1 Foundation, n.d.)

Applicability to Clinical Practice
Primary care is often the first point of entry for many patients
with obstructive airway diseases making it an ideal
environment in which to implement new strategies for
improved detection of alpha-1 antitrypsin deficiency. Fromer
(2010) proposed the following process maps aimed at
improving diagnosis and management of AATD in the primary
care setting.
3a.

3b.

Figure 3a. Proposed process map for AATD screening in the primary care setting
Figure 3b. Proposed diagnosis algorithm for AATD planned care follow-up in the primary
care setting.
Image from: Fromer, L. (2010). Improving diagnosis and management of alpha-1 antitrypsin
deficiency in primary care: translating knowledge into action. COPD, 7(3), 192–8.
https://doi.org/10.3109/15412555.2010.482577
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